Nasdaq grants Evogene a second 180-day window to meet $1 bid rule

Go back to Nasdaq grants Evogene a second 180-day window to meet $1 bid rule

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

September 30, 2026 7:15 AM EDT

REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the Company received a letter (the... More